172 related articles for article (PubMed ID: 21647565)
1. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.
Kim KS; Lee WK
Jpn J Ophthalmol; 2011 Jul; 55(4):370-377. PubMed ID: 21647565
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
5. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
6. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
Lee SY; Kim JG; Joe SG; Chung H; Yoon YH
Korean J Ophthalmol; 2008 Jun; 22(2):92-9. PubMed ID: 18612226
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
9. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
Lee JH; Lee WK
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Lai TY; Chan WM; Liu DT; Luk FO; Lam DS
Br J Ophthalmol; 2008 May; 92(5):661-6. PubMed ID: 18356265
[TBL] [Abstract][Full Text] [Related]
13. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
Komuku Y; Iwahashi C; Gomi F
Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
Kim SJ; Yu HG
Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
19. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
Ngo WK; Chee WK; Tan CS; Lim TH
BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
[TBL] [Abstract][Full Text] [Related]
20. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]